戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 r virus function, as well as new targets for antisense therapeutics.
2  action and hampered clinical development of antisense therapeutics.
3 oping potent, cost-effective, self-permeable antisense therapeutics.
4 leotides have been crucial to the success of antisense therapeutics.
5 mRNA molecule constitutes a major problem in antisense therapeutics.
6 roup a leading choice for incorporation into antisense therapeutics.
7 l-2-targeted antisense G3139 as archetypical antisense therapeutics.
8 plication of peptide nucleic acids (PNAs) as antisense therapeutics.
9 ides have been crucial to the development of antisense therapeutics.
10                     Given their relevance in antisense therapeutics, a DNA/RNA synthesizer-compatible
11 es, which may represent a promising group of antisense therapeutic agents.
12  establish FHNA as a useful modification for antisense therapeutics and also confirm the stabilizing
13 ead to identification of clinically relevant antisense therapeutics and can identify which molecular
14 a cause of C9ORF72 ALS and provide candidate antisense therapeutics and candidate human pharmacodynam
15 establish tcDNA as a useful modification for antisense therapeutics and highlight the role of chemica
16  picomoles of remaining protecting groups on antisense therapeutics and oligonucleotide diagnostics.
17 be a potentially useful delivery vehicle for antisense therapeutics and/or target validation.
18 y may have good potential for diagnostic and antisense therapeutic applications.
19 e modifications currently being evaluated as antisense therapeutics are tolerated by the enzyme, amon
20 hosphoramidates are promising candidates for antisense therapeutics, as well as for diagnostic applic
21 not only in designing new SARS-CoV-2 and DMD antisense therapeutics, but also for rapid development o
22  reported here are relevant to the design of antisense therapeutics comprised of these modifications.
23 olecular biology, but also for the design of antisense therapeutic constructs.
24 ls is a central goal of chemical biology and antisense therapeutic development.
25 n significant progress in the development of antisense therapeutics for a wide range of medicinal app
26  of the major barriers to the development of antisense therapeutics has been their poor bioavailabili
27 as been hindered by poor in vivo delivery of antisense therapeutics to tumor cells.
28 over novel oligonucleotide modifications for antisense therapeutics, we have prepared oligodeoxyribon